FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283027744> ?p ?o ?g. }

• W4283027744 endingPage "2994" @default.
• W4283027744 startingPage "2994" @default.
• W4283027744 abstract "Immunotherapy is changing the therapeutic landscape of many hematologic diseases, with immune checkpoint inhibitors, bispecific antibodies, and CAR-T therapies being its greatest expression. Unfortunately, immunotherapy in acute myeloid leukemia (AML) has given less brilliant results up to now, and the only approved drug is the antiCD33 antibody-drug conjugate gemtuzumab ozogamicin. A promising field of research in AML therapy relies on anti-leukemic vaccination to induce remission or prevent disease relapse. In this review, we analyze recent evidence on AML vaccines and their biological mechanisms. The principal proteins that have been exploited for vaccination strategies and have reached clinical experimental phases are Wilm's tumor 1, proteinase 3, and RHAMM. the majority of data deals with WT1-base vaccines, given also the high expression and mutation rates of WT1 in AML cells. Stimulators of immune responses such as TLR7 agonist and interleukin-2 have also proven anti-leukemic activity both in vivo and in vitro. Lastly, cellular vaccines mainly based on autologous or allogeneic off-the-shelf dendritic cell-based vaccines showed positive results in terms of T-cell response and safety, also in elderly patients. Compared to other immunotherapeutic strategies, anti-AML vaccines have the advantage of being a less toxic and a more manageable approach, applicable also to elderly patients with poorer performance status, and may be used in combination with currently available therapies. As for the best scenario in which to use vaccination, whether in a therapeutic, prophylactic, or preemptive setting, further studies are needed, but available evidence points to poorer results in the presence of active or high-burden disease. Given the poor prognosis of relapsed/refractory or high-risk AML, further research is urgently needed to better understand the biological pathways that sustain its pathogenesis. In this setting, research on novel frontiers of immunotherapy-based agents, among which vaccines represent important actors, is warranted to develop new and efficacious strategies to obtain long-term disease control by immune patrolling." @default.
• W4283027744 created "2022-06-18" @default.
• W4283027744 creator A5043295492 @default.
• W4283027744 creator A5043587598 @default.
• W4283027744 creator A5045941713 @default.
• W4283027744 creator A5049869778 @default.
• W4283027744 creator A5058553911 @default.
• W4283027744 creator A5072176434 @default.
• W4283027744 creator A5086540907 @default.
• W4283027744 date "2022-06-17" @default.
• W4283027744 modified "2023-10-01" @default.
• W4283027744 title "Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?" @default.
• W4283027744 cites W1558724806 @default.
• W4283027744 cites W1576062071 @default.
• W4283027744 cites W1785074005 @default.
• W4283027744 cites W1976101370 @default.
• W4283027744 cites W1978607297 @default.
• W4283027744 cites W1983973479 @default.
• W4283027744 cites W1992343552 @default.
• W4283027744 cites W1995778815 @default.
• W4283027744 cites W1996606215 @default.
• W4283027744 cites W1999214231 @default.
• W4283027744 cites W2008036289 @default.
• W4283027744 cites W2010109838 @default.
• W4283027744 cites W2025021551 @default.
• W4283027744 cites W2025079459 @default.
• W4283027744 cites W2027857664 @default.
• W4283027744 cites W2028092080 @default.
• W4283027744 cites W2038676366 @default.
• W4283027744 cites W2046154718 @default.
• W4283027744 cites W2064727084 @default.
• W4283027744 cites W2067069532 @default.
• W4283027744 cites W2069382319 @default.
• W4283027744 cites W2075287181 @default.
• W4283027744 cites W2094772445 @default.
• W4283027744 cites W2106084333 @default.
• W4283027744 cites W2135948744 @default.
• W4283027744 cites W2139423334 @default.
• W4283027744 cites W2148301776 @default.
• W4283027744 cites W2152217218 @default.
• W4283027744 cites W2165887202 @default.
• W4283027744 cites W2519109143 @default.
• W4283027744 cites W2537146822 @default.
• W4283027744 cites W2557326294 @default.
• W4283027744 cites W2559537906 @default.
• W4283027744 cites W2560536699 @default.
• W4283027744 cites W2584750434 @default.
• W4283027744 cites W2594017563 @default.
• W4283027744 cites W2606935378 @default.
• W4283027744 cites W2715749014 @default.
• W4283027744 cites W2747973325 @default.
• W4283027744 cites W2787301955 @default.
• W4283027744 cites W2787663719 @default.
• W4283027744 cites W2788365551 @default.
• W4283027744 cites W2883812891 @default.
• W4283027744 cites W2886748809 @default.
• W4283027744 cites W2890693336 @default.
• W4283027744 cites W2901659598 @default.
• W4283027744 cites W2946806795 @default.
• W4283027744 cites W2976997434 @default.
• W4283027744 cites W2983686108 @default.
• W4283027744 cites W3010583755 @default.
• W4283027744 cites W3022543485 @default.
• W4283027744 cites W3048827006 @default.
• W4283027744 cites W3157227887 @default.
• W4283027744 cites W3159185078 @default.
• W4283027744 cites W3163829944 @default.
• W4283027744 cites W3175757912 @default.
• W4283027744 cites W3185917757 @default.
• W4283027744 cites W3210540945 @default.
• W4283027744 cites W4200201081 @default.
• W4283027744 cites W4211166898 @default.
• W4283027744 doi "https://doi.org/10.3390/cancers14122994" @default.
• W4283027744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35740657" @default.
• W4283027744 hasPublicationYear "2022" @default.
• W4283027744 type Work @default.
• W4283027744 citedByCount "8" @default.
• W4283027744 countsByYear W42830277442022 @default.
• W4283027744 countsByYear W42830277442023 @default.
• W4283027744 crossrefType "journal-article" @default.
• W4283027744 hasAuthorship W4283027744A5043295492 @default.
• W4283027744 hasAuthorship W4283027744A5043587598 @default.
• W4283027744 hasAuthorship W4283027744A5045941713 @default.
• W4283027744 hasAuthorship W4283027744A5049869778 @default.
• W4283027744 hasAuthorship W4283027744A5058553911 @default.
• W4283027744 hasAuthorship W4283027744A5072176434 @default.
• W4283027744 hasAuthorship W4283027744A5086540907 @default.
• W4283027744 hasBestOaLocation W42830277441 @default.
• W4283027744 hasConcept C10205521 @default.
• W4283027744 hasConcept C143998085 @default.
• W4283027744 hasConcept C176290653 @default.
• W4283027744 hasConcept C203014093 @default.
• W4283027744 hasConcept C22070199 @default.
• W4283027744 hasConcept C2777701055 @default.
• W4283027744 hasConcept C2778623314 @default.
• W4283027744 hasConcept C2778729363 @default.
• W4283027744 hasConcept C28328180 @default.
• W4283027744 hasConcept C3875195 @default.

• next